Cargando…
Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
Glioblastoma (GBM) is the most common primary brain tumor occurring in America. Despite recent advances in therapeutics, the prognosis for patients with newly diagnosed GBM remains dismal. As these tumors characteristically show evidence of angiogenesis (neovascularization) there has been great inte...
Autores principales: | Ahluwalia, Manmeet S., Gladson, Candece L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850510/ https://www.ncbi.nlm.nih.gov/pubmed/20379377 http://dx.doi.org/10.1155/2010/689018 |
Ejemplares similares
-
Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas
por: Shirai, Katsuyuki, et al.
Publicado: (2012) -
Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma
por: Rahman, Ruman, et al.
Publicado: (2010) -
Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012) -
Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
por: Haidl, Friederike, et al.
Publicado: (2017) -
Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells
por: Nakabayashi, Hiromichi, et al.
Publicado: (2010)